As of 2015, 30.3 million Americans – or 9.4% of the US population – have diabetes and another 84.1 million Americans have prediabetes, according to a recently-released report from the Centers for Disease Control and Prevention.
As of 2015, 30.3 million Americans — or 9.4% of the US population – have diabetes and another 84.1 million Americans have prediabetes, according to a recently-released report from the Centers for Disease Control and Prevention.
The National Diabetes Statistics Report, released approximately every 2 years, provides information on diabetes prevalence and incidence, prediabetes, risk factors for complications, acute and long-term complications, mortality, and costs in the United States.
Although the findings indicate that the rate of new diabetes diagnoses is holdign steady, thanks in large part to diabetes management and prevention programs, diabetes remained the seventh leading cause of death in the US in 2015. The report also includes county-level data for the first time, and shows that some areas of the country bear a heavier diabetes burden than others.
Key findings from the National Diabetes Statistics Report note that:
“Although these findings reveal some progress in diabetes management and prevention, there are still too many Americans with diabetes and prediabetes,” CDC Director Brenda Fitzgerald, MD said in a press release about the findings.
To reduce the impact of prediabetes and type 2
, officials with the CDC established the National Diabetes Prevention Program (National DPP), which provides the framework for type 2 diabetes prevention efforts in the U.S. Based on the landmark Diabetes Prevention Program research findings funded by the National Institutes of Health (NIH), the National DPP includes an evidence-based, year-long, behavior change program to improve eating habits and increase physical activity to lose a modest amount of weight and significantly reduce the risk of type 2 diabetes.
FDA Approves Omalizumab to Reduce Food-Based Allergic Reactions in Adult and Pediatric Patients
February 21st 2024This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.